News Headlines

31. Ellison Medical Institute And UniQuest Enter Exclusive License To Advance Novel Prostate Cancer Therapy Toward First-In-Human Studies 6/22/2026

    The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new treatment for advanced and therapy-resistant prostate cancer, toward first-in-human studies.

32. Lonza And InduPro Announce Licensing Agreement To Advance Next-Generation ADC Therapeutics 6/22/2026

    Lonza and InduPro, a biotechnology company pioneering next-generation therapeutics through the targeted proximity of cell-surface proteins, today announced a new licensing agreement to support the advancement of innovative antibody-drug conjugate (ADC) therapies.

33. Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits 6/22/2026

    Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., today announced that it completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past fiscal year.

34. Quantoom And Nucelion Therapeutics To Expand RNA Capacity In India 6/22/2026

    Quantoom (operating as Phoenix Biosciences SA) and Nucelion Therapeutics Private Limited today announced the signing of a Memorandum of Understanding (MoU) to explore a preferred RNA contract development and manufacturing (CDMO) partnership in India.

35. Antengene Announces Exclusive License Agreement With MPM BioImpact-Established K2 Therapeutics For ATG-106 And Option For Undisclosed Bispecific TCE 6/21/2026

    Antengene Corporation Limited ("Antengene", SEHK: [6996 HK]), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it has entered into an exclusive license agreement ("License Agreement") with K2 Therapeutics for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) in development for solid tumors.

36. Telos Biotech Announces Strategic Evaluation Collaboration With Made Scientific To Assess TELOVANCE Across Multiple Cell Therapy Manufacturing Platforms 6/19/2026

    Telos Biotech, Inc. (“Telos”), a biotechnology company developing TELOVANCE, a telomerase-based telomere lengthening platform designed for use in ex vivo cell therapy manufacturing, today announced a strategic evaluation collaboration with Made Scientific, Inc. (“Made Scientific”), a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO).

37. Zemcelpro® (UM171 Cell Therapy) Licensing And Supply Agreements Announced For Canada 6/19/2026

    ExCellThera Inc. ("ExCellThera"), a global leader in blood stem cell expansion and metabolic fitness technologies, together with its wholly owned subsidiary Cordex Biologics ("Cordex"), today announced exclusive licensing and supply agreements granting Medexus the Canadian commercialization rights for Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy.

38. The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing 6/18/2026

    The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

39. Minaris Enhances GMP Cell Banking Suites At Philadelphia Facility 6/18/2026

    Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, today announced the enhancement of its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. 

40. Organon And Samsung Bioepis Expand Agreement To Commercialize PYZCHIVA (ustekinumab), A Biosimilar Referencing STELARA (ustekinumab) In Canada 6/18/2026

    Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA, Samsung Bioepis’s biosimilar referencing STELARA (ustekinumab).